Evolving AAV-delivered therapeutics towards ultimate cures

Gene therapy has entered a new era after decades-long efforts, where the recombinant adeno-associated virus (AAV) has stood out as the most potent vector for in vivo gene transfer and demonstrated excellent efficacy and safety profiles in numerous preclinical and clinical studies. Since the first AA...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Xiangjun, Urip, Brian Anugerah, Zhang, Zhenjie, Ngan, Chun Christopher, Feng, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885987/
https://www.ncbi.nlm.nih.gov/pubmed/33594520
http://dx.doi.org/10.1007/s00109-020-02034-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885987/
https://www.ncbi.nlm.nih.gov/pubmed/33594520
http://dx.doi.org/10.1007/s00109-020-02034-2

Ejemplares similares